CRSP News and Press, CRISPR Therapeutics AG From 04/01/24

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therap...

2024-03-31 17:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-30 06:50:00 ET The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them. Three Motley Fool contributors believe they've identified three stocks that fit the bill. Here's why they think CRISPR Therapeutics...

2024-03-30 03:03:34 ET Summary CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation. The approval of CASGEVY, the first CRISPR-based medicine, for transfusion-dependent β-thalasse...

2024-03-28 10:47:02 ET Microsoft Corporation (MSFT) MSFT is trading DOWN for the last 4 days, and it at trading at $421.22 with volume of 3,479,535 and a one day change of $-0.21 (-0.05%). Microsoft Corporation has a 52-week low of 272.05 and a 52-week high of $430.82. The business'...

2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...

2024-03-26 02:33:22 ET Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insur...

2024-03-23 06:45:00 ET Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks. Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (NASDAQ: AXSM) , CRISPR Therapeutics (NASDAQ: CRSP)...

2024-03-18 11:02:46 ET More on bluebird bio Bluebird Bio: Innovative Therapies, Monetary Setbacks Biotech And Pharma Diversification Pays Off bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Biggest stock movers today: EQT, MESO, Crypto...

2024-03-16 08:45:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is gaining in prominence. The gene-editing specialist has made tremendous clinical and regulatory progress since its 2016 initial public offering, leading to market-beating returns even if it hasn't always been smooth sailing...